Coronary Artery Calcium & Plaque

The scan works because calcium in arterial walls absorbs X-rays differently than soft tissue. The CT machine detects those dense deposits across four major coronary arteries, assigns a density score to each, and the computer multiplies volume by density to produce the final Agatston score. It was developed by Arthur Agatston at the University of Miami in the early 1990s, and despite decades of newer imaging, it remains the most validated single number in preventive cardiology.

What the scan is not: it is not a picture of your arteries in motion. It does not show blood flow. It does not directly visualize blockages. It does not measure soft plaque, which is the non-calcified buildup that is often more dangerous acutely. Those require different tools, which we discuss in Q9, Q17, and Q19. The CAC scan is a census of what has already hardened in your arterial walls, and hardening takes time. A score above zero tells you atherosclerosis has been present long enough to mineralize.

The MESA study followed 6,814 people with no known heart disease and found that CAC score independently predicted heart attack and stroke above and beyond traditional risk factors including cholesterol and blood pressure (Detrano R et al, NEJM 2008, DOI: 10.1056/NEJMoa0707423). That study built the evidence base for the 2018 ACC/AHA guidelines recommending CAC as a tiebreaker in borderline-risk patients.

The CAC scan is a blunt instrument. It is fast, cheap (often $100 to $200 out of pocket), involves about 1 millisievert of radiation (comparable to a mammogram), and requires no preparation beyond removing metal jewelry. It answers one question: how much calcium has accumulated in your coronary artery walls.

The CCTA answers a richer set of questions: it can show how narrowed a vessel is, identify soft plaque that the CAC scan misses, characterize plaque morphology, and in advanced centers produce a CT-derived fractional flow reserve (CT-FFR) that simulates the hemodynamic effect of a stenosis. The SCOT-HEART trial showed that CCTA-guided management reduced fatal and non-fatal MI at five years compared to standard care (Williams MC et al, NEJM 2019, DOI: 10.1056/NEJMoa1805971). The radiation dose for CCTA is typically 3 to 5 millisieverts, and the contrast dye carries a small risk in patients with kidney disease or contrast allergy.

In clinical practice, I order CAC for asymptomatic patients where I want to refine risk before committing to statin therapy, and I order CCTA when a patient has symptoms suggestive of coronary disease, or when a high CAC score raises questions about stenosis that a calcium number alone cannot answer. The two tests are not interchangeable. They answer different questions.

The 2018 ACC/AHA Cholesterol Guideline recommends CAC as a "risk enhancer" in patients aged 40 to 75 who are in the borderline to intermediate cardiovascular risk category and where the statin decision is uncertain (Grundy SM et al, Circulation 2019, DOI: 10.1161/CIR.0000000000000625). The key phrase there is "where the decision is uncertain." If your 10-year risk is already above 20 percent based on standard calculators, you start a statin regardless of CAC. The scan earns its value when the risk calculator spits out 8 to 12 percent and you and your physician are genuinely uncertain about next steps.

There is a separate argument for ordering CAC in younger men, 35 to 45, who have strong family histories or known metabolic abnormalities like elevated Lp(a) or familial hypercholesterolemia. A man who knows his grandfather and father both had heart attacks before 55 deserves more than a "come back in ten years." In that setting, even a CAC of zero is informative, and a CAC above zero before 45 changes the clinical conversation sharply. I discuss this in more detail in Q16 (premature CAC).

Insurance rarely covers CAC for primary prevention in younger patients, so cost matters. At $100 to $200 in most markets, I find it is one of the few tests where the out-of-pocket price is low enough that cost should not be the deciding factor for most working-age men.

The cardiovascular literature has historically been male-dominated, and CAC research is no exception. But the data we have for women are reassuring. The MESA cohort included women, and CAC predicted events in women comparably to men. A CAC score of zero in a woman aged 55 to 65 confers a very low 10-year event rate, while a CAC above 300 at that age places her at a risk level equivalent to a diabetic woman, regardless of her other traditional risk factors (Michos ED et al, JACC 2014, DOI: 10.1016/j.jacc.2014.09.030).

There are sex-specific risk conditions that heighten the argument for earlier CAC in women: preeclampsia during pregnancy doubles a woman's lifetime cardiovascular risk. Premature menopause before age 45 is an independent risk factor. Autoimmune conditions like lupus and rheumatoid arthritis carry cardiovascular risk that standard calculators underestimate. In any woman with these histories, I would not wait until 55 to discuss CAC screening.

The clinical reality is that women are less likely than men to be referred for CAC and less likely to be started on statins despite equivalent or higher risk. A CAC score in a woman with borderline risk changes that conversation the same way it does in men, and the evidence supports using it.

Radiation risk is cumulative and real, and it is worth being honest about it rather than dismissing it. The estimated lifetime cancer risk from a single 1 mSv exposure is approximately 1 in 10,000 for a 50-year-old adult. To put that in perspective, the annual background radiation risk from living in the United States is about 3 mSv, and a transatlantic flight delivers roughly 0.04 mSv. The scan adds a small, quantifiable increment to your lifetime radiation exposure.

Where this matters: a 35-year-old who is borderline appropriate for CAC should have the radiation conversation because the longer lifespan means more time for any induced cancer to manifest. A 60-year-old with multiple risk factors should not let the radiation question delay a clinically important test. The absolute risk from 1 to 3 mSv in someone aged 50 or above is vanishingly small compared to the risk of undetected, untreated high-grade coronary disease.

Repeat scanning does add radiation. This is one reason I am selective about when to repeat a CAC scan (see Q13). The clinical convention is not to repeat more frequently than every three to five years in most patients, and even then only when the result would change management.

The cost landscape is one of the genuine oddities of American healthcare. A test with substantial mortality-prediction data (Budoff MJ et al, JACC 2018, DOI: 10.1016/j.jacc.2017.10.033) is not covered by most insurance plans because it falls under "screening" for a condition the patient does not yet have. Statins cost three to ten dollars per month at generic prices. The CAC scan that determines whether to prescribe those statins costs more out of pocket than a year of the medication itself.

In practice, most patients in my clinic who need a CAC scan can access one for $99 to $150 at a local imaging center or hospital outpatient department. Some hospitals offer periodic "Heart Scan" promotions at reduced rates. The American College of Cardiology has advocated for broader insurance coverage; as of 2026, coverage remains fragmented.

For patients with active coronary symptoms, insurance coverage improves substantially because the indication shifts from screening to diagnostic evaluation. A CCTA ordered for chest pain evaluation will often be covered; a CAC scan ordered for pure risk stratification in an asymptomatic patient typically will not. I tell my patients this upfront, and for most of them, $150 is a reasonable out-of-pocket investment for a test that may settle a ten-year statin debate in one afternoon.

The zero score is the most reassuring result in preventive cardiology, and it deserves precision about what that reassurance does and does not cover. In MESA, adults with a CAC of zero had a 10-year heart attack and stroke rate of about 1 percent, compared to rates of 7 to 15 percent or higher in those with CAC above 300 (Detrano R et al, NEJM 2008, DOI: 10.1056/NEJMoa0707423). That is real, clinically meaningful protection. A borderline-risk patient who gets a zero score and declines statin therapy is making a defensible decision based on good evidence.

But three things can undermine the zero.

First: soft, non-calcified plaque (see Q8 and Q9). Young arteries that are actively building unstable plaque may not yet have mineralized that plaque into detectable calcium. A 38-year-old with a strong family history and elevated Lp(a) can have a CAC of zero and a CCTA showing significant non-calcified plaque. This is uncommon but not rare.

Second: the zero has a half-life. Plaque that is soft today may calcify over the next five years and reappear as a measurable score. The MESA risk calculator includes a "CAC progression" estimate that accounts for this.

Third: a zero score does not mean your other risk factors disappeared. An LDL of 165 is still an LDL of 165 after a zero CAC. You do not get to stop managing the inputs just because the current output looks clean.

Atherosclerosis progresses through stages. The earliest plaques are lipid-rich, non-calcified, and sometimes described as "soft" or "vulnerable." Over time, they can calcify, at which point the CAC scan detects them. A young arterial wall with active, unstable plaque may not yet have undergone calcification. This is not a theoretical caveat. A study of symptomatic patients undergoing CCTA found that 20 to 30 percent of those with obstructive coronary disease had a CAC score of zero (Gottlieb I et al, JACC Cardiovasc Imaging 2010, DOI: 10.1016/j.jcmg.2010.03.009). These are symptomatic patients, which matters, but the finding challenges the assumption that zero automatically means clean arteries.

In clinical practice, I worry most about the zero-CAC, high-Lp(a) patient. Lp(a) is an inherited lipoprotein that promotes plaque formation and thrombosis through mechanisms partly independent of LDL. A 44-year-old man with Lp(a) of 150 nmol/L and a CAC of zero may not be the low-risk patient his calcium score suggests. A CCTA would provide more complete information in that setting.

This does not mean the zero score is not useful. For the typical 52-year-old with borderline risk and no special risk enhancers, a zero CAC is genuinely reassuring and clinically useful. The zero-with-soft-plaque scenario is an exception, not the rule.

The biology of plaque is more varied than most patients realize. An atherosclerotic plaque begins as an infiltration of oxidized LDL particles into the arterial intima, followed by an inflammatory response, macrophage recruitment, and the formation of a lipid-rich necrotic core. That early, lipid-rich plaque is mechanically unstable. Its fibrous cap can rupture, exposing the thrombogenic core to flowing blood and triggering the acute clot that causes a heart attack. This vulnerable plaque does not yet contain enough calcium to be visible on a CAC scan.

Over time, plaques undergo calcification. The same inflammatory process that builds the plaque eventually drives calcium phosphate deposition, and calcified plaques, paradoxically, may be more mechanically stable than their soft predecessors. This is the biological basis for the athlete paradox discussed in Q42: heavily calcified plaque in a long-distance runner may represent old, stable disease rather than active, vulnerable disease.

The clinical implication is that a CAC scan tells you about the stable, calcified end of the plaque spectrum. A CCTA tells you about the full spectrum. New AI-based plaque analysis tools (see Q39) are beginning to characterize plaque composition automatically from CCTA data, which may eventually allow clinicians to identify vulnerable plaque non-invasively on a population scale. We are not there yet.

The absolute risk associated with a CAC of 100 is not the same at age 45 as it is at age 65. A 45-year-old man with a CAC of 100 is at the 90th percentile for his age group, which is clinically alarming. A 68-year-old man with a CAC of 100 is below the median for his age group and may actually be in a relatively favorable position given what typically accumulates by that age.

The MESA study showed that CAC above 100 was associated with a hazard ratio of approximately 3.5 for hard coronary events compared to CAC of zero, across all age groups studied (Detrano R et al, NEJM 2008, DOI: 10.1056/NEJMoa0707423). A separate analysis from Budoff and colleagues in JACC 2018 showed that CAC above 100 was associated with meaningful increases in all-cause mortality, not just cardiovascular mortality (Budoff MJ et al, JACC 2018, DOI: 10.1016/j.jacc.2017.10.033).

What a CAC of 100 means clinically: in the 2018 ACC/AHA guidelines, a score above 100 is sufficient to reclassify a borderline-risk patient to intermediate or high risk, which in practice typically means initiating statin therapy if not already on it, setting a more aggressive LDL target, and increasing the urgency of lifestyle modification discussions. I also check ApoB and Lp(a) in anyone with a score in this range, because the calcium tells me something happened; those additional markers help tell me why.

When a patient hands me a report showing CAC 400, the first thing I do is put it in percentile context using the MESA calculator. A 72-year-old woman with a score of 400 is near the median for her demographic. A 48-year-old man with 400 is in the 95th percentile, which changes the urgency considerably.

The calcium itself does not dissolve with statin therapy. Statins do not act like a drain cleaner for coronary calcification. What they do is reduce the lipid core of non-calcified plaque, reduce inflammation, and in some trials appear to cause paradoxical increases in CAC score even while reducing events. This apparent paradox is explained in Q15. The calcium you see on a scan may represent stabilized, calcified plaques that are less likely to rupture than the non-calcified plaques that statins have resolved.

Clinically, a score of 400 in a patient not already on maximally-tolerated statin therapy triggers the following in my practice: high-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg), LDL target below 70 mg/dL with ApoB below 80 mg/dL, discussion of ezetimibe if LDL target not reached on statin alone, and consideration of CCTA if there are any symptoms suggesting ischemia. I also check for obstructive sleep apnea, because it is underdiagnosed and amplifies cardiovascular risk substantially.

The MESA study enrolled 6,814 men and women aged 45 to 84 from six U.S. cities, followed them for over a decade, and published extensive data on how CAC scoring refines risk prediction. The resulting calculator at mesa-nhlbi.org takes your age, sex, race/ethnicity, total cholesterol, HDL, LDL, systolic blood pressure, blood pressure medication use, smoking status, diabetes status, family history, and CAC score and produces a 10-year CHD risk estimate with and without the CAC contribution.

The power of the tool is visible when you run a person twice: once with their standard risk factors only, and once adding their CAC score. A 55-year-old man with borderline traditional risk factors might come out at 9 percent on the standard calculation. If his CAC is zero, that number drops to 3 or 4 percent. If his CAC is 300, it rises to 18 or 20 percent. That reclassification is not cosmetic. It changes whether statin therapy is indicated, how aggressively you target LDL, and whether to consider additional testing.

The MESA calculator is freely available and takes about two minutes to complete. I encourage patients in the borderline risk range to use it as a conversation-starter before their appointment, not to make clinical decisions without a physician, but to understand why the CAC number is not just a number. It is a modifier of every other number on your lab report.

The decision to rescan is not always obvious, and guidelines are less prescriptive here than for the initial scan. The clinical logic is: does the new number change what I do? If a patient has a CAC of zero and is declining statin therapy based on that result, knowing whether their score has risen to 50 or 100 over five years would change the conversation. A rescan makes sense there. If a patient already has a score of 600, is on maximally-tolerated statin therapy with an LDL of 55, and is compliant with lifestyle modifications, knowing whether the score is now 620 or 680 does not change management and adds another 1 to 2 mSv of radiation.

The MESA study found that zero-CAC patients who were rescanned five years later had detectable calcium in about 20 to 25 percent of cases, and that those who converted from zero to positive had a significant jump in event rate (Kronmal RA et al, JACC 2007, DOI: 10.1016/j.jacc.2007.01.060). This supports the argument for a scheduled rescan at three to five years in zero-score patients with ongoing risk factors.

I do not rescan patients on maximally-tolerated statin therapy with established high CAC unless a clinical question arises (new symptoms, therapeutic failure, unexplained progression) that a new scan would answer. Radiation, cost, and the risk of clinical information that does not change management all argue against reflexive rescanning.

This is a question I answer carefully, because the wrong answer discourages patients. "No, your score will not go down" sounds like defeat. What is actually true is more interesting and more useful.

Statin therapy does not reduce CAC scores. The ASTEROID trial and others show that intensive statin therapy can reduce total atheroma volume on intravascular ultrasound, meaning the lipid-rich, non-calcified component of plaque can regress with sufficient LDL reduction. But that regression is invisible to the CAC scan. The CAC scan sees the calcium, and calcium deposited in arterial walls largely stays there.

What does change with treatment is CAC progression. Studies measuring serial CAC over years show that patients on statins have slower annual increases in calcium score compared to those not on statins. The MESA study's serial data showed that CAC progression greater than 15 Agatston units per year was associated with significantly higher event rates, independent of baseline CAC (Budoff MJ et al, Circulation 2013, DOI: 10.1161/CIRCULATIONAHA.112.147272). Slowing that progression is a legitimate therapeutic goal.

The practical answer: do not expect your score to drop. Expect it to stop rising as fast. The score you have is the scar of what your arteries went through. The trajectory going forward is what we are changing.

This finding was initially alarming to both patients and clinicians when it emerged from serial CAC studies. The JUPITER trial and subsequent analyses noted that patients on rosuvastatin had faster CAC progression than placebo, while simultaneously having fewer heart attacks (Criqui MH et al, JACC 2014, DOI: 10.1016/j.jacc.2014.03.022). The biological explanation rests on plaque biology: statins reduce the lipid core of non-calcified plaques and reduce inflammation. As a result, plaques that were soft and potentially rupture-prone may undergo accelerated calcification, becoming denser and more stable. The CAC scanner sees this as a higher score.

This is called the "statin calcification effect" and it represents one of the limitations of using serial CAC as a treatment monitoring tool. If you start a statin and your CAC rises from 150 to 250 over three years, that number in isolation looks like bad news. In the context of an LDL that dropped from 145 to 68, it may represent stabilized, calcified, less-dangerous plaque.

The clinical implication: do not use serial CAC scores as the primary metric for statin treatment response. LDL, ApoB, and clinical event rates are better treatment monitors. Serial CAC is most useful before statin initiation, as a risk-stratification tool, not during treatment, as a response-monitoring tool.

Age is built into the interpretation of CAC precisely because atherosclerosis is time-dependent. A 68-year-old man with a CAC of 50 is essentially on schedule for his age group, possibly below median. A 38-year-old man with a CAC of 50 has been building calcified plaque in his coronary arteries for years before his peers, which means something in his biology or environment is driving accelerated disease.

The differential for premature CAC includes familial hypercholesterolemia (FH), elevated Lp(a), diabetes, smoking, and hypertension in younger adults. A study from the Copenhagen General Population Study found that individuals with detectable CAC before age 50 had a hazard ratio for myocardial infarction of approximately 4.2 compared to age-matched zero-score peers (Mortensen MB et al, JACC 2019, DOI: 10.1016/j.jacc.2018.12.017). That is not a subtle signal.

In clinical practice, a young person with premature CAC gets a full lipid panel including ApoB and Lp(a), a fasting glucose and HbA1c, family history deep-dive, and usually a cascade screening recommendation for first-degree relatives. Familial hypercholesterolemia is diagnosed in fewer than 10 percent of the estimated 1.3 million Americans who have it; premature CAC in a young person is one of the most reliable triggers to think about it.

The distinction matters because patients and clinicians often conflate "amount of plaque" with "calcium score." These are not the same. A person can have substantial non-calcified plaque and a CAC of zero. A person can have a high CAC score with little active non-calcified plaque. The relationship between the two is probabilistic, not one-to-one.

Plaque morphology on CCTA is now described using standardized systems that classify lesions as calcified, non-calcified, or mixed. Non-calcified plaques are further characterized by density: low-attenuation plaque (very soft, lipid-rich) correlates with high-risk morphology on histopathology (Motoyama S et al, JACC 2007, DOI: 10.1016/j.jacc.2007.06.053). The SCOT-HEART trial found that CCTA-guided care improved outcomes partly by identifying patients with obstructive non-calcified plaque who would have been missed by a CAC scan alone.

From a practical standpoint: the CAC scan gives you the calcified plaque inventory. The CCTA gives you the full inventory. When a patient has a CAC of zero but ongoing symptoms or very high Lp(a) or strong family history, I want the full inventory, not just the calcified fraction.

The mechanism of most heart attacks is plaque rupture. A lipid-rich, thin-capped plaque erodes or ruptures, exposes its thrombogenic core to circulating blood, and triggers acute clot formation. Calcified plaque has a different structural profile: the calcium deposit within the plaque makes it stiffer and more resistant to the mechanical stresses that cause rupture. This is the biological basis for the claim that calcification represents plaque stabilization.

But the calcification itself is not entirely benign. Spotty calcification, which appears as small calcium deposits scattered within a largely non-calcified plaque, may actually increase local mechanical stress at the calcium-tissue interface and may paradoxically increase rupture risk (Vengrenyuk Y et al, PNAS 2006, DOI: 10.1073/pnas.0505539103). Dense sheet calcification is more protective. The distinction between spotty and dense calcification on imaging is one of the areas where AI-based plaque analysis tools are beginning to add clinical value.

From a patient communication standpoint: if someone has a high CAC score and wants to know whether they should be more or less worried than someone with the same calcium score who has significant non-calcified plaque on CCTA, the answer is less worried about an acute event in the short term, more worried about long-term arterial disease and hemodynamic consequences of stenosis. Both need treatment.

The clinical decision tree between CAC and CCTA maps roughly onto symptom status. An asymptomatic person with traditional risk factors and an uncertain statin decision gets a CAC scan. A person with chest pain on exertion, atypical chest discomfort, or unexplained dyspnea gets a CCTA (or stress testing, depending on the presentation). A CCTA answers questions that the CAC scan cannot: is there a flow-limiting stenosis? What does the plaque burden look like in total, including the non-calcified component? Is there a specific lesion in the LAD that might explain these symptoms?

The 2021 ACC/AHA chest pain guidelines explicitly moved CCTA to a higher position in the diagnostic algorithm for stable chest pain, partly based on SCOT-HEART and PROMISE trial data (Gulati M et al, JACC 2021, DOI: 10.1016/j.jacc.2021.07.053). CCTA has a negative predictive value close to 99 percent for significant coronary stenosis, meaning a normal CCTA in a patient with chest pain is highly reassuring.

In practice, I have also ordered CCTA in asymptomatic high-CAC patients, particularly those above age 55 with CAC above 300, to understand the distribution and severity of disease before making additional treatment decisions beyond statin therapy. The calcium score tells me how much. The CCTA tells me where and what kind.

Fractional flow reserve (FFR) was originally a pressure-wire measurement obtained during cardiac catheterization. A wire is passed across a stenosis, pressures are measured on both sides, and a ratio below 0.80 indicates hemodynamically significant obstruction warranting intervention. CT-FFR uses advanced computational fluid dynamics applied to the CCTA image to simulate the same measurement without the catheter.

The NXT trial showed that CT-FFR had good diagnostic accuracy for predicting invasive FFR values (Douglas PS et al, JACC 2015, DOI: 10.1016/j.jacc.2015.05.069). HeartFlow, the commercial CT-FFR platform, has been cleared by the FDA and is available at a number of U.S. academic centers. The technology has evolved to the point where it can reduce rates of unnecessary catheterization in patients with intermediate stenosis on CCTA.

In practice, CT-FFR is not a first-line test for most patients with high CAC. It comes into the workflow after a CCTA shows a stenosis in the 40 to 70 percent range where the hemodynamic significance is uncertain. If the stenosis is below 40 percent, it is generally not hemodynamically significant regardless of FFR. If it is above 70 percent in a major vessel, most cardiologists will refer for catheterization directly. CT-FFR is most useful in the middle range.

Plaque regression was considered impossible through much of the 20th century. The landmark REVERSAL and ASTEROID trials changed that understanding. ASTEROID used intravascular ultrasound (IVUS) to measure total coronary plaque volume before and after 24 months of high-intensity rosuvastatin therapy (40 mg daily). The result was a statistically significant regression of total atheroma volume: median percent change in total atheroma volume was -0.98 percent, the first demonstration of regression with statin monotherapy in a large clinical trial (Nissen SE et al, JAMA 2006, DOI: 10.1001/jama.295.13.1556).

The GLAGOV trial, discussed in more detail in Q24, extended this finding by showing that adding evolocumab to statin therapy in patients with coronary disease produced significantly more plaque regression than statin alone, in proportion to the additional LDL reduction achieved.

The clinical implication is that regression of non-calcified plaque is real, measurable, and proportional to the degree of LDL reduction achieved. The necessary LDL target appears to be below 70 mg/dL to stabilize and below 50 to 55 mg/dL to see meaningful regression. This is one of the strongest clinical arguments for intensive lipid-lowering in high-risk patients: we are not merely preventing new plaque, we are reducing existing plaque.

The REVERSAL trial compared pravastatin 40 mg to atorvastatin 80 mg in 502 patients with coronary artery disease and found that high-intensity statin therapy arrested plaque progression while moderate-intensity therapy allowed slow progression (Nissen SE et al, JAMA 2004, DOI: 10.1001/jama.291.9.1071). ASTEROID (2006) then showed actual regression with even higher-intensity rosuvastatin. GLAGOV (2016) added evolocumab to statin therapy and showed significantly greater regression, with the greatest regression in patients achieving LDL below 50 mg/dL (Nicholls SJ et al, JAMA 2016, DOI: 10.1001/jama.2016.16951).

More recent CCTA-based studies using AI plaque quantification software have expanded the evidence to non-calcified plaque volumes measured less invasively. The PACMAN-AMI trial showed that alirocumab added to statin therapy produced IVUS-measured plaque regression in patients presenting with acute MI (Räber L et al, JAMA 2022, DOI: 10.1001/jama.2022.5218).

What is not yet established is whether imaging-measured plaque regression independently reduces clinical events beyond what LDL reduction alone predicts. The regression studies are hypothesis-generating for the mechanism; the hard-event data come from the large PCSK9 inhibitor outcome trials like FOURIER and ODYSSEY.

The GLAGOV trial provides the clearest dose-response data. Patients were stratified by achieved LDL and plaque regression rates were plotted against LDL quartile. In the lowest quartile, achieving LDL around 30 mg/dL on combined statin plus evolocumab therapy, regression was observed in the majority of patients. In the highest quartile, where LDL remained around 90 mg/dL, progression continued. The regression-progression threshold appeared to lie around an LDL of 70 mg/dL.

This has direct clinical implications. A patient on a moderate-dose statin with an LDL of 95 is not in regression territory. They may be slowing progression, but the plaque is probably still growing. Getting to 68 changes the trajectory. Getting to 45 changes it more. This is the clinical argument for not settling at "LDL is under 100" in a high-risk patient. The biology of regression demands a lower target.

The 2022 ACC Expert Consensus Decision Pathway for PCSK9 inhibitors (Writing Committee, JACC 2022, DOI: 10.1016/j.jacc.2022.03.001) endorses LDL targets below 55 mg/dL in very high-risk patients, partly on the basis of this regression evidence. In patients with recent ACS, established CAD, or very high CAC scores, I now routinely target LDL below 55 using statin plus ezetimibe, and add a PCSK9 inhibitor when needed to reach that target.

The GLAGOV design: 968 patients with established CAD on background statin therapy, randomized to evolocumab 420 mg monthly or placebo, IVUS measurements at baseline and 78 weeks. The primary endpoint was percent atheroma volume change. Evolocumab reduced LDL from a median of 92 mg/dL to 36 mg/dL. Percent atheroma volume decreased by 0.95 percent in the evolocumab group and increased by 0.05 percent in the placebo group, a significant difference (p < 0.001). Sixty-four percent of evolocumab patients experienced plaque regression versus 47 percent of placebo patients (Nicholls SJ et al, JAMA 2016, DOI: 10.1001/jama.2016.16951).

Why it matters: GLAGOV moved PCSK9 inhibitors from a purely LDL-lowering story to a plaque regression story. It provided biological evidence that the magnitude of LDL reduction achievable with PCSK9 inhibition produces a measurable change in the arterial wall, not just a change in a blood test number. This was important because it provided a plausible mechanism linking the dramatic LDL reductions of evolocumab to the clinical outcomes shown in FOURIER.

The limitation is that GLAGOV was an imaging study, not a hard-outcomes trial. Plaque volume is a surrogate. The hard-event evidence comes from FOURIER and ODYSSEY-OUTCOMES.

Family history of premature coronary artery disease (first-degree male relative with MI before 55, or female relative before 65) is a legitimate independent risk factor in every major risk calculator. But it carries statistical weight as a binary yes/no variable, and within the "yes" category there is enormous heterogeneity. A man whose father had a heart attack at 53 and smoked two packs a day for thirty years has a different inherited risk than a man whose father had a heart attack at 53, never smoked, ran marathons, and had no other identifiable risk factors.

The MESA cohort data show that CAC added independent predictive value over and above family history in every subgroup analyzed. In a direct comparison, individuals with positive family history but CAC of zero had event rates similar to those without family history, while individuals without family history but CAC above 100 had event rates far above those with family history alone (Detrano R et al, NEJM 2008, DOI: 10.1056/NEJMoa0707423).

The clinical implication is that family history should trigger a CAC scan, not substitute for one. A 48-year-old man with a strong paternal history deserves to know whether that inherited risk has translated into actual arterial disease. Knowing the CAC is 0 versus 180 changes the conversation completely, in a way that knowing only "positive family history" never can.

The disconnect between standard lipid panels and actual coronary risk is one of the most common sources of false reassurance I encounter in clinic. A man with an LDL of 118 and a father who had bypass surgery at 57 is not a low-risk patient simply because his LDL falls within the "desirable" range. His ApoB may be 155. His Lp(a) may be elevated. His CAC may already be positive.

In the MESA data, approximately 25 percent of individuals with traditional low-risk lipid profiles had detectable CAC, meaning they had arterial disease that standard risk calculators would have underestimated (Detrano R et al, NEJM 2008, DOI: 10.1056/NEJMoa0707423). Among those with positive family history, the proportion with detectable CAC despite low-risk labs is higher.

The strong-family-history, normal-labs patient is also the patient most likely to be dismissed by a physician who is relying on calculators and feels reassured by the numbers. He is the patient who walks out of a physical thinking he got a clean bill of health when what he actually got was a clean lipid panel. Those are not the same thing. A CAC scan at age 40 to 45 in this patient is not aggressive medicine. It is basic due diligence.

The Pooled Cohort Equations (PCE) are the current ACC/AHA-endorsed tool for estimating 10-year ASCVD risk. They incorporate age, sex, race/ethnicity, total cholesterol, HDL, systolic blood pressure, blood pressure treatment, diabetes, and smoking status. They are reasonably well-calibrated but have known limitations in the borderline-risk range (10-year risk 7.5 to 20 percent) where they are imprecise.

A series of analyses from the MESA cohort, along with independent data from the Multi-Ethnic Study and other cohorts, consistently find that CAC adds significant discriminatory power above the PCE. The C-statistic, a measure of model discrimination, typically improves from around 0.75 to 0.82 or higher when CAC is incorporated. Net reclassification improvement, a more clinically interpretable metric, shows that CAC correctly reclassifies 20 to 30 percent of borderline-risk patients into higher or lower risk categories (Rana JS et al, JACC 2016, DOI: 10.1016/j.jacc.2015.12.014).

A longer-term mortality analysis from Budoff et al, following over 66,000 patients from six imaging centers, found that CAC above 100 was independently associated with significantly higher all-cause mortality, even after adjustment for age, sex, and traditional risk factors (Budoff MJ et al, JACC 2018, DOI: 10.1016/j.jacc.2017.10.033). The implication: the calcium score predicts mortality, not just heart attack.

This is a question I answer with complete honesty because it is a real clinical consideration, not a trivial one. A 48-year-old man who is shopping for a $2 million life insurance policy and is in the underwriting process should understand that if his CAC comes back at 650, the insurer may request that result and may use it to rate him as a substandard risk.

Health insurance, under ACA rules, cannot use a CAC score or any other health condition as a basis for premium variation. This protection is significant. But life insurance, long-term care insurance, and disability insurance are not covered by ACA rules. Underwriters for these products routinely ask about cardiac imaging, exercise stress tests, and other diagnostic results.

The practical advice: if you are actively in the underwriting process for life or disability insurance, speak with your insurance broker before obtaining elective CAC imaging. This is not a reason to avoid a clinically indicated scan, but the timing matters. Once the policy is issued, new diagnoses generally cannot change your locked-in terms.

For most of my patients who are not actively seeking new life insurance, this concern is outweighed by the clinical value of knowing their CAC score. The information is more useful to you than it is dangerous to your financial planning.

The radiation concern is the most scientifically grounded of these hesitations. A 35-year-old who receives 1 to 3 mSv of radiation has more life-years ahead during which any radiation-induced cancer could theoretically develop. This is a legitimate calculation, and it is one reason I discuss it explicitly with younger patients. The practical answer is that modern low-dose protocols reduce exposure to under 1 mSv, and that the lifetime cancer risk from a single scan at age 35 is vanishingly small in absolute terms.

The anxiety concern is real in clinical practice. A 38-year-old who gets a CAC score of 80 when he came in feeling healthy will experience anxiety regardless of whether that anxiety is clinically justified. Some cardiologists, particularly those without preventive subspecialty training, feel this anxiety-induction is a harm. I understand that view. My counter is that the anxiety a 38-year-old feels when he learns he has coronary calcification is productive anxiety; it changes behavior in ways that a risk calculator number printed on a lab report does not.

The institutional habit explanation is the least defensible of the three. Some generalists and internists simply have not integrated CAC scanning into their practice patterns and default to "come back in ten years." For a 40-year-old man with familial hypercholesterolemia, a father with a stent at 52, and an Lp(a) of 180 nmol/L, that default is not conservative medicine. It is neglect with paperwork.

In the MESA cohort, the study population began at age 45. The existing epidemiological data for CAC in 30-year-olds is sparse. Population studies in young adults, including autopsy studies from the PDAY (Pathobiological Determinants of Atherosclerosis in Youth) and Bogalusa Heart Study, show that early fatty streaks and fibrous plaques can be present in the 20s and 30s in individuals with risk factors, but calcification is uncommon before the mid-to-late 30s.

A 30-year-old with heterozygous familial hypercholesterolemia and a father who had a CABG at 45 is a different patient than the typical 30-year-old. In that setting, I would seriously consider a CCTA rather than a CAC scan, precisely because non-calcified plaque is more likely to be the relevant finding at that age. A CAC of zero at 30 in an FH patient is not as reassuring as it would be at 55, because the biology of plaque at that age is dominated by soft, non-calcified material.

The more practical answer for most 30-year-olds: check ApoB, Lp(a), fasting glucose, blood pressure, and body composition. Build the preventive foundation. Get the CAC scan when the clinical picture warrants it, typically late 30s to early 40s if risk factors are present.

The MESA serial imaging data followed 3,004 initially zero-CAC participants over five years. Approximately 22 percent developed detectable CAC by the five-year follow-up. Among those who converted to positive, the median score was around 22 Agatston units, though a subset progressed more rapidly. Predictors of conversion included age, male sex, hypertension, diabetes, and current smoking (Kronmal RA et al, JACC 2007, DOI: 10.1016/j.jacc.2007.01.060).

In clinical practice, rapid CAC progression is more likely in patients who were already on the trajectory toward early calcification and whose risk factors went unmanaged. A 46-year-old with untreated hypertension, LDL of 160, and a family history who gets a CAC of zero today should not be told the result is reassuring indefinitely. The scan captured a moment. Without managing the risk factors, the moment will pass.

The practical implication is that a zero CAC result is a strong short-term reassurance but not a five-year hall pass. If the underlying risk factors persist, I want to rescan in three to five years. If the risk factors are well-managed and the patient is truly low-risk, I may extend to five to seven years before reconsidering.

Lipoprotein(a) is an inherited, LDL-like particle with a unique apolipoprotein(a) tail that inhibits fibrinolysis and promotes inflammation in the arterial wall. Population studies consistently show that Lp(a) above approximately 50 mg/dL (or roughly 125 nmol/L) is independently associated with cardiovascular events. The mechanism is partly through direct plaque formation and partly through a prothrombotic effect that compounds plaque vulnerability.

MESA data show that elevated Lp(a) was associated with greater CAC prevalence and higher CAC scores at baseline, even after adjustment for LDL and other standard risk factors (Guan W et al, Arterioscler Thromb Vasc Biol 2012, DOI: 10.1161/ATVBAHA.112.249953). Longitudinal data also suggest faster CAC progression over time in high-Lp(a) individuals.

The clinical problem is that statins do not lower Lp(a). They may modestly raise it in some patients. Niacin lowers it but is no longer recommended due to a lack of outcome benefit in trials. PCSK9 inhibitors reduce Lp(a) by 20 to 30 percent. RNA-based therapies currently in late-stage trials (pelacarsen, olpasiran) reduce Lp(a) by 80 to 90 percent and represent the most promising therapeutic advance for this risk factor. For now, elevated Lp(a) in a patient with elevated CAC means I target LDL even more aggressively, since LDL remains the one modifiable target in that pair.

This is one of the most common clinical paradoxes I explain to patients. A man who presents with a CAC score of 2,400 and no symptoms, no prior events, and reasonable exercise tolerance is often bewildered and so, candidly, is his referring physician. The counterintuitive explanation is that extreme calcification is not the same as extreme instability.

The biology: plaque that calcifies is plaque that has undergone a form of stabilization. Dense calcium deposits make the plaque structurally rigid and less prone to the fibrous cap rupture that triggers acute MI. A patient with a CAC of 2,000 may have had a period of very active lipid-rich plaque formation years earlier that has since burned through and calcified. His arteries are full of old war damage, but the active combat may have subsided.

This does not mean high-CAC patients are not at risk. Budoff et al's mortality data show dose-dependent mortality risk up through the highest CAC categories (Budoff MJ et al, JACC 2018, DOI: 10.1016/j.jacc.2017.10.033). But the risk is more concentrated in long-term events, hemodynamic compromise from stenosis, and the small subset of patients who still have active non-calcified plaque alongside their calcium burden. In a very-high-CAC patient with no symptoms, I want a CCTA to see the luminal impact, and I optimize lipid, blood pressure, and metabolic management aggressively.

The statin decision in the borderline-risk range has been a clinical headache for two decades. Standard risk calculators produce a 10-year risk estimate of, say, 11 percent, and the physician and patient must decide whether to initiate therapy that will continue for decades, with its attendant small side-effect risks and monitoring requirements, or continue watchful waiting. This is the clinical problem CAC was built to solve.

The JACC 2018 guideline framework is explicit: if 10-year risk is 7.5 to 20 percent (borderline to intermediate) and the statin decision is uncertain, measure CAC. If CAC is zero, the statin may be deferred with reassessment in one to three years (assuming no other risk enhancers). If CAC is 1 to 99, moderate-intensity statin is recommended. If CAC is 100 or above, high-intensity statin is recommended (Grundy SM et al, Circulation 2019, DOI: 10.1161/CIR.0000000000000625).

This framework has good clinical logic. A patient with a CAC of zero who declines statin therapy based on shared decision-making is not making an irrational choice. A patient with a CAC of 180 who refuses statin therapy based on side-effect fears is making a more consequential decision, and the clinical conversation should reflect that.

The threshold at which LDL reduction becomes urgent is lower than most patients expect. An LDL of 120 in a man with a CAC of 350 is not acceptable in 2026. The biology of plaque progression, the regression data from IVUS studies, and the event reduction data from PCSK9 inhibitor trials all point toward lower is better, with no evidence of a lower bound for harm in the LDL range achievable with modern therapy.

Clinically, I have migrated toward ApoB as my primary treatment target in high-CAC patients, alongside LDL. ApoB measures the number of atherogenic lipoprotein particles directly; LDL measures the cholesterol carried within LDL particles. A patient can have an LDL of 72 and an ApoB of 115 simultaneously (because small, dense LDL particles carry less cholesterol per particle), meaning the LDL target has been reached while the particle count remains high. In a patient who just revealed a CAC of 400, I want both LDL below 70 and ApoB below 80 mg/dL.

If statin plus ezetimibe does not achieve those targets, PCSK9 inhibitors are the next step. The 2022 ACC Expert Consensus on PCSK9 inhibitors includes high CAC as an indication for escalating therapy beyond statin monotherapy in certain high-risk profiles.

Inflammation is central to plaque instability. The events preceding plaque rupture involve macrophage activation, cytokine release, and thinning of the fibrous cap. Imaging inflammation directly would identify vulnerable plaques before they rupture, the holy grail of cardiac imaging. We are not there clinically, but several approaches are in late-stage development or limited clinical use.

FDG-PET/CT (fluorodeoxyglucose positron emission tomography) uses glucose uptake as a surrogate for metabolic activity. Inflamed plaques take up more glucose and appear as "hot spots" on PET. The limitation is that the coronary arteries are small and subject to cardiac motion, making coronary PET technically difficult. FDG-PET is better validated for aortic and carotid plaque inflammation (Tawakol A et al, Lancet 2017, DOI: 10.1016/S0140-6736(16)31714-7).

18F-NaF PET, which detects active microcalcification as a marker of unstable plaque, has shown promise in small studies for identifying high-risk coronary plaques. A Scottish cohort study found that 18F-NaF uptake in coronary plaques predicted subsequent MI (Dweck MR et al, Lancet 2012, DOI: 10.1016/S0140-6736(12)61398-6). This is an active area of investigation but not yet in routine clinical use.

Pericoronary fat attenuation is discussed in detail in Q37.

The biology behind FAI rests on a simple observation: adipose tissue surrounding coronary arteries responds to local vascular inflammation by altering its lipid content and density. When a coronary artery wall is inflamed, the pericoronary fat becomes less lipid-rich and more dense on CT. This density change is measurable as a shift in Hounsfield units and is expressed as the fat attenuation index.

The Oxford group published key validation data for FAI in 2018. In a cohort of 3,912 patients undergoing CCTA, high pericoronary FAI around the right coronary artery was associated with a significantly elevated risk of cardiac mortality over 5 years, independent of traditional risk factors and total plaque burden (Oikonomou EK et al, Nature Medicine 2018, DOI: 10.1038/s41591-018-0223-9). The association held even in patients with low or zero CAC scores.

The clinical translation of FAI is being driven partly by AI analysis platforms that can compute it automatically from standard CCTA datasets. The CLEARPATH FAI score and similar tools are being evaluated for routine clinical deployment. As of 2026, FAI is not in standard CCTA reports at most centers, but it is available at academic centers and as an add-on analysis through commercial AI platforms.

The value of FAI is that it addresses the fundamental limitation of the CAC scan: it provides a window into active arterial inflammation rather than historical calcium accumulation.

The standard CCTA report gives a radiologist's qualitative or semi-quantitative description of coronary anatomy: stenosis percentages, plaque distribution, dominant vessel. CLEERLY performs automated, quantitative plaque volumetry across all plaque subtypes, producing numeric outputs (volume of calcified plaque, volume of low-attenuation plaque, total plaque volume) that are more reproducible and more detailed than standard reporting.

The clinical rationale for CLEERLY is strongest in patients where total non-calcified plaque burden would change management. A patient with a CAC of 80 might have minimal total plaque on CLEERLY analysis (mostly calcified, limited soft component) or significant total non-calcified plaque (much more concerning). A patient being considered for PCSK9 inhibitor therapy beyond statin alone might benefit from quantitative baseline plaque measurement to track regression.

The evidence base for CLEERLY outcomes is still developing. Cross-sectional validation studies confirm its plaque measurements correlate with IVUS-measured plaque volumes. Longitudinal outcomes data comparing CLEERLY-guided care to standard care are pending. As of 2026, CLEERLY is best characterized as a detailed characterization tool for already-indicated CCTA rather than a primary screening tool.

The promise of AI in cardiac imaging is genuine. Human readers are slow, variable, and focused on specific clinical questions (is there stenosis? is there plaque?). AI can process every voxel of a CT dataset systematically, characterize tissue density, classify plaque subtypes, and produce quantitative outputs in minutes with high reproducibility. The CCTA dataset that takes a radiologist 20 minutes to read can yield 40 distinct quantitative measurements of plaque subtype, volume, and location through AI analysis.

The evidence for clinical benefit, as opposed to measurement accuracy, is still accumulating. CLEERLY and similar platforms can tell you that you have 142 mm³ of low-attenuation plaque in your LAD. What is less clear is whether that specific number changes clinical outcomes when used to guide therapy versus standard LDL and risk-based treatment decisions. The landmark trials needed to establish that clinical benefit are running now.

From a patient-facing perspective: if you are seeing a preventive cardiologist at an academic center and CCTA has been ordered for good clinical reasons, asking whether AI-based plaque analysis is available is a reasonable question. If you are a low-risk person wondering whether to pay $600 for AI plaque analysis as a screening tool, the evidence does not yet support that investment.

The cardiovascular risk of HRT in postmenopausal women is nuanced and depends heavily on timing (the "timing hypothesis" or "window of opportunity"), formulation, and route of administration. Starting HRT within five to ten years of menopause in healthy, low-cardiovascular-risk women is associated with a neutral to modestly favorable cardiovascular profile. Starting HRT in women over 60 or more than ten years post-menopause with existing arterial disease carries higher risk.

The 2020 Menopause Society guidelines and the 2022 NICE menopause guidelines both note that women with significant cardiovascular risk should have a thorough risk assessment before initiating HRT, particularly oral combined estrogen-progestogen therapy. A CAC scan in a 58-year-old woman with borderline cardiovascular risk who is considering oral HRT gives the prescribing clinician information that changes the risk-benefit discussion. A CAC of zero is reassuring. A CAC of 450 changes the conversation toward transdermal preparations and lower systemic estrogen exposure.

This is not a widely discussed indication for CAC scanning in clinical guidelines, but it is a logical application of existing evidence. Preventive cardiologists and gynecologists who manage complex HRT decisions increasingly discuss CAC as part of that workup.

The question comes from a reasonable intuition: if exercise causes cardiac stress and muscle adaptation, might it also cause some form of calcification in coronary vessels? The answer from the available data is no, not directly. Calcification is a slow, years-long biological process driven by lipid accumulation, inflammation, and repair mechanisms in the arterial wall. A single marathon does not trigger arterial calcification. Decades of intense endurance training may be associated with higher CAC scores, but through mechanisms related to the metabolic demands and possibly minor arterial injury from repeated high-intensity training, not through any acute post-exercise effect.

The prospective data in this area are limited. Cross-sectional studies comparing endurance athletes to sedentary controls show higher CAC prevalence and scores in heavy endurance trainers, with the association appearing strongest in those with the highest lifetime training volumes (Aengevaeren VL et al, Circulation 2017, DOI: 10.1161/CIRCULATIONAHA.117.028996). But these studies cannot establish causality, and the confounding effect of athletes' dietary habits, lipid profiles, and genetic factors is difficult to disentangle.

The athlete-CAC paradox was brought into clinical focus by a series of studies in Masters athletes, long-distance cyclists, and veteran marathon runners. Studies of Tour de France alumni showed higher CAC scores than age-matched controls but fewer cardiovascular events, suggesting the standard prognostic framework for CAC required modification in this group (Mohlenkamp S et al, European Heart Journal 2008, DOI: 10.1093/eurheartj/ehn358).

The proposed mechanism is plaque stabilization through exercise. High levels of aerobic fitness are associated with lower arterial inflammation, higher HDL, better insulin sensitivity, and other plaque-stabilizing factors. Decades of endurance training may accelerate the calcification of lipid-rich plaques, turning them from soft and vulnerable to dense and stable. The result is a CAC score that looks alarming by standard criteria but represents predominantly stable, calcified disease.

The clinical limitation is that this effect cannot be assumed for every high-CAC athlete. An athlete with a high CAC score and mixed plaque (some dense calcification, some low-attenuation non-calcified areas) is at different risk than one with exclusively dense calcium. A CCTA with plaque characterization in a high-CAC endurance athlete gives more complete information than the calcium score alone.

The paradox was examined in a widely discussed 2017 Circulation study by Aengevaeren and colleagues, which found that lifetime exercise dose showed a J-shaped relationship with CAC: light to moderate exercisers had the lowest CAC, while the most intense lifelong exercisers had CAC scores comparable to sedentary high-risk individuals (Aengevaeren VL et al, Circulation 2017, DOI: 10.1161/CIRCULATIONAHA.117.028996). Importantly, when CAC-positive athletes and CAC-positive sedentary individuals were compared for event rates, the athletes had lower rates, suggesting the same calcium score carried different prognostic weight.

The explanation most favored in the cardiology literature is the plaque morphology hypothesis discussed in Q42: athletes' plaques are predominantly dense and calcified rather than soft and rupture-prone. The competing explanation is selection bias: athletes who have had significant events or symptoms have already been identified and treated, leaving a surviving cohort of very-high-fitness, high-CAC individuals who appear healthy partly because the sick ones have been removed.

The practical clinical guidance for Masters athletes: do not dismiss a high CAC score because you are fit. Get a CCTA to characterize plaque morphology. Use the full clinical picture, including functional capacity, plaque characterization, and traditional risk factors, before deciding that your CAC score is "athlete's CAC" rather than standard high-risk disease.

The concern about heavy lifting and coronary disease is partly historical, rooted in case reports of exercise-triggered events and the physiologic reality that intense resistance exercise raises blood pressure transiently to very high levels. A Valsalva-associated surge to 200/120 during a maximum deadlift is real and is a legitimate consideration in patients with known severe coronary stenosis and ischemic symptoms.

But for the asymptomatic patient with a high CAC score and no functional limitation, the evidence does not support restricting resistance training. Multiple large cohort studies show that regular resistance exercise reduces cardiovascular mortality and all-cause mortality, including in populations with elevated cardiovascular risk. The 2023 ACC/AHA Physical Activity Guidelines recommend muscle-strengthening activities two or more days per week for adults with or at risk for cardiovascular disease.

If a patient has a CAC above 400 and has never had a functional assessment, I typically order a stress test before clearing them for maximal-intensity training. Not to restrict them if the test is normal, but to confirm that the coronary anatomy is not producing ischemia at high workloads. A normal stress test in a high-CAC patient clears them for vigorous exercise from a stenosis standpoint.

The terminology is confusing because patients use "heart scan" generically. When a physician orders a CAC scan, it is a CT-based, low-radiation study focused on calcium in coronary artery walls. When a physician orders a cardiac MRI, they are typically evaluating myocardial structure, function, perfusion, or fibrosis, not coronary plaque. The two tests operate on different principles and have different clinical indications.

Cardiac MRI is the gold standard for evaluating cardiomyopathy, myocarditis, cardiac sarcoidosis, arrhythmogenic cardiomyopathy, and the extent of myocardial fibrosis after a heart attack. Late gadolinium enhancement (LGE) on cardiac MRI identifies areas of myocardial scarring with high spatial resolution. Cardiac MRI does not image calcium in coronary arteries well and is not a substitute for CAC scoring or CCTA for plaque assessment.

Where the two intersect: a patient who has had a heart attack and is being evaluated for myocardial damage and residual function will often get both a CCTA (to evaluate the coronary anatomy) and a cardiac MRI (to evaluate myocardial viability and function). In this setting they are complementary, not redundant.

From a pure CAC-and-plaque discussion standpoint, cardiac MRI is not part of the standard toolkit. If a patient asks whether they should get a cardiac MRI instead of a CAC scan for plaque assessment, the answer is no. The MRI will not answer that question.

Performing both tests in the same session is clinically logical when the physician needs both the calcium score (for risk stratification and baseline) and the anatomical detail of the CCTA (for stenosis characterization or plaque morphology). This is commonly done in patients with intermediate-high clinical risk where both a risk number and anatomical detail are needed for management decisions.

The combined protocol does increase total radiation and cost compared to either test alone. Insurers often cover the CCTA portion when there is an appropriate clinical indication (chest pain, known coronary disease) but not the CAC component as a pure screening addition. The additional radiation from the CAC acquisition, typically 1 to 2 mSv, is added to the CCTA dose.

From a workflow standpoint: the CAC is acquired without contrast injection during normal breathing. The CCTA is then performed with contrast injection, typically requiring beta-blockade to lower heart rate for optimal image quality, and a nitroglycerin sublingual dose to dilate coronary vessels. The combined session takes about 30 to 45 minutes including preparation, not significantly longer than the CCTA alone.

A CAC score of 400 does not tell you whether any of the plaque is causing significant narrowing that restricts blood flow. A patient with a CAC of 400 and a normal exercise stress test may have predominantly calcified, non-obstructive plaque scattered across multiple vessel segments without causing hemodynamic compromise. A patient with a CAC of 400 and ST depression at low workloads on a stress test has obstructive CAD until proven otherwise.

The 2021 ACC/AHA Chest Pain guidelines place stress testing and CCTA as roughly equivalent options for stable chest pain evaluation, with CCTA preferred in patients with intermediate pre-test probability (Gulati M et al, JACC 2021, DOI: 10.1016/j.jacc.2021.07.053). For asymptomatic high-CAC patients, stress testing is not universally recommended, but it is reasonable in patients planning to begin or intensify exercise programs, particularly those with CAC above 300.

In my practice, a high-CAC patient who wants to return to vigorous activity or who is starting an intense training program gets a stress test to confirm there is no ischemia at high workloads. Not as a barrier, but as due diligence. A normal stress test in that patient is clinically meaningful and permits confident exercise prescription.

The aspirin story in primary prevention is one of the most instructive case studies in how medicine reverses itself when large, well-controlled trials challenge earlier assumptions. The ASPREE trial enrolled 19,114 adults over 70 with no known cardiovascular disease and found that aspirin 100 mg daily did not reduce major adverse cardiovascular events and was associated with significantly higher rates of major bleeding, including intracranial hemorrhage (McNeil JJ et al, NEJM 2018, DOI: 10.1056/NEJMoa1805819). ARRIVE and ASCEND produced similar findings in different populations.

In the context of high CAC specifically: a 2021 JACC analysis examined whether high CAC modified the aspirin benefit in borderline-risk patients and found that even among CAC-positive individuals, the net benefit of aspirin in primary prevention was not clearly favorable when bleeding risk was incorporated. The 2022 USPSTF updated its aspirin recommendation to discourage initiation of aspirin for primary prevention in adults 60 and older.

There is a theoretical argument that a patient with a CAC of 300 or above is not truly "primary prevention" in the same sense as someone with a CAC of zero, because they have established arterial disease. Some preventive cardiologists use CAC above 300 or above the 75th percentile as a trigger for aspirin in patients aged 40 to 59. This is a defensible individualized decision but is not guideline-supported as a universal recommendation.

Colchicine is an anti-inflammatory agent long used for gout. Its mechanism in cardiovascular disease involves inhibition of the NLRP3 inflammasome, neutrophil function, and other inflammatory pathways relevant to plaque instability and thrombosis. The COLCOT trial (2019) showed that colchicine 0.5 mg daily significantly reduced major cardiovascular events in patients shortly after acute MI (Tardif JC et al, NEJM 2019, DOI: 10.1056/NEJMoa1912388). LoDoCo2 extended this finding to patients with stable chronic coronary disease (Nidorf SM et al, NEJM 2020, DOI: 10.1056/NEJMoa2021372).

Both trials enrolled patients with established coronary artery disease, not asymptomatic CAC-positive individuals. The extrapolation to high-CAC primary prevention patients is logical but not data-driven. A person with a CAC of 400 and no prior events is not the same population as the LoDoCo2 cohort. Whether colchicine benefits asymptomatic high-CAC patients is the subject of ongoing trials including CLEAR Arteries.

The side-effect profile of low-dose colchicine is generally acceptable. The main concern is gastrointestinal intolerance, which occurs in about 5 to 10 percent of patients. A small excess of non-cardiovascular mortality was noted in LoDoCo2, which has not been explained but is being monitored. At 0.5 mg daily for indefinite use, the risk-benefit calculation in primary prevention requires better evidence before I routinely recommend it.

This is a question that deserves a direct answer rather than a hedge, so here is mine.

The CAC score wins the single-number contest for a specific reason: it is not a prediction. It is an observation. When a calculator tells you that you have a 12 percent 10-year risk, it is telling you something about the statistical behavior of people who resemble you. When a CAC scan shows you a score of 280, it is showing you something that has happened inside your own arteries. Those are different kinds of information, and the second kind changes patients' behavior and clinicians' decisions in ways the first kind does not.

The runners-up deserve mention. ApoB is a close second, because it is the most direct measure of circulating atherogenic particle burden and tracks plaque progression and regression more sensitively than LDL. Lp(a) is the third choice, because it is inherited, largely unmodifiable, and strongly predictive in subsets of patients who look risk-normal by every other metric. If I could give a 40-year-old man one blood test that would tell me something truly new, it would be Lp(a).

But as a single number that captures decades of cardiovascular history, distinguishes truly low-risk from deceptively low-risk patients, and changes the therapeutic decision at the moment of uncertainty: the CAC score.

The 47-year-old engineer from Decatur who opened this section had all the right labs and all the wrong arteries. His CAC told us both what had happened and what to do next. That is more than most numbers can claim.